Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/INSR_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/INSR_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/INSR_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/INSR_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/INSR_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/INSR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/INSR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/INSR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00462099 | Endometrium | AEH | nitric oxide metabolic process | 17/2100 | 81/18723 | 7.69e-03 | 4.33e-02 | 17 |
GO:00434707 | Endometrium | AEH | regulation of carbohydrate catabolic process | 13/2100 | 56/18723 | 7.92e-03 | 4.40e-02 | 13 |
GO:00328811 | Endometrium | AEH | regulation of polysaccharide metabolic process | 11/2100 | 44/18723 | 7.92e-03 | 4.40e-02 | 11 |
GO:20010579 | Endometrium | AEH | reactive nitrogen species metabolic process | 17/2100 | 82/18723 | 8.71e-03 | 4.75e-02 | 17 |
GO:00068099 | Endometrium | AEH | nitric oxide biosynthetic process | 16/2100 | 76/18723 | 9.26e-03 | 4.99e-02 | 16 |
GO:004603417 | Endometrium | EEC | ATP metabolic process | 107/2168 | 277/18723 | 1.32e-31 | 3.95e-28 | 107 |
GO:001598015 | Endometrium | EEC | energy derivation by oxidation of organic compounds | 97/2168 | 318/18723 | 5.37e-20 | 3.58e-17 | 97 |
GO:001603217 | Endometrium | EEC | viral process | 112/2168 | 415/18723 | 2.48e-18 | 1.35e-15 | 112 |
GO:000609115 | Endometrium | EEC | generation of precursor metabolites and energy | 125/2168 | 490/18723 | 3.76e-18 | 1.88e-15 | 125 |
GO:000989617 | Endometrium | EEC | positive regulation of catabolic process | 108/2168 | 492/18723 | 2.55e-11 | 3.64e-09 | 108 |
GO:004440317 | Endometrium | EEC | biological process involved in symbiotic interaction | 73/2168 | 290/18723 | 7.47e-11 | 9.95e-09 | 73 |
GO:003133117 | Endometrium | EEC | positive regulation of cellular catabolic process | 94/2168 | 427/18723 | 4.30e-10 | 4.45e-08 | 94 |
GO:005170117 | Endometrium | EEC | biological process involved in interaction with host | 54/2168 | 203/18723 | 2.67e-09 | 2.01e-07 | 54 |
GO:004259314 | Endometrium | EEC | glucose homeostasis | 56/2168 | 258/18723 | 2.26e-06 | 6.61e-05 | 56 |
GO:003350014 | Endometrium | EEC | carbohydrate homeostasis | 56/2168 | 259/18723 | 2.56e-06 | 7.39e-05 | 56 |
GO:004346714 | Endometrium | EEC | regulation of generation of precursor metabolites and energy | 34/2168 | 130/18723 | 3.36e-06 | 9.13e-05 | 34 |
GO:004341011 | Endometrium | EEC | positive regulation of MAPK cascade | 89/2168 | 480/18723 | 4.21e-06 | 1.08e-04 | 89 |
GO:002241116 | Endometrium | EEC | cellular component disassembly | 82/2168 | 443/18723 | 1.06e-05 | 2.26e-04 | 82 |
GO:000689815 | Endometrium | EEC | receptor-mediated endocytosis | 51/2168 | 244/18723 | 1.89e-05 | 3.50e-04 | 51 |
GO:190165314 | Endometrium | EEC | cellular response to peptide | 68/2168 | 359/18723 | 2.75e-05 | 4.83e-04 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INSR | SNV | Missense_Mutation | | c.3652N>C | p.Asp1218His | p.D1218H | P06213 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSR | SNV | Missense_Mutation | | c.3556N>C | p.Glu1186Gln | p.E1186Q | P06213 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSR | SNV | Missense_Mutation | | c.2585N>C | p.Phe862Ser | p.F862S | P06213 | protein_coding | tolerated(0.88) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSR | SNV | Missense_Mutation | | c.1889N>T | p.Ser630Leu | p.S630L | P06213 | protein_coding | deleterious(0.01) | possibly_damaging(0.459) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
INSR | SNV | Missense_Mutation | | c.487N>G | p.Ile163Val | p.I163V | P06213 | protein_coding | tolerated(0.06) | benign(0.123) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
INSR | SNV | Missense_Mutation | | c.2072C>G | p.Ser691Cys | p.S691C | P06213 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
INSR | insertion | In_Frame_Ins | novel | c.2752_2753insTGGCACAATCTCAGCTCACTGTAGCCTCCGCCTCCCGGGTTCAAG | p.Pro918delinsLeuAlaGlnSerGlnLeuThrValAlaSerAlaSerArgValGlnAla | p.P918delinsLAQSQLTVASASRVQA | P06213 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSR | insertion | Frame_Shift_Ins | novel | c.1227_1228insAGAAAATGTATTGA | p.Leu412CysfsTer8 | p.L412Cfs*8 | P06213 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSR | insertion | Frame_Shift_Ins | novel | c.1226_1227insGGGAAGTGACTGCCAAGTTGAAGTTAGGAGTG | p.Phe409LeufsTer17 | p.F409Lfs*17 | P06213 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSR | deletion | Frame_Shift_Del | novel | c.2222delN | p.Phe741SerfsTer30 | p.F741Sfs*30 | P06213 | protein_coding | | | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | Metformin glycinate | | 22974412 |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201644 | INSULIN ZINC SUSP RECOMBINANT HUMAN | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201638 | INSULIN SUSP PROTAMINE ZINC PURIFIED PORK | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201639 | INSULIN ZINC SUSP BEEF | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201496 | INSULIN ASPART | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | BMS-754807 | BMS-754807 | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | CENISERTIB | CENISERTIB | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | Insulin-lispro | | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | AEW-541 | AEW-541 | |